Denintuzumab (hBU 12) (CAS: 1630074-14-4) is a humanized monoclonal antibody targeting CD19, used in the development of antibody-drug conjugates (ADCs) for B-cell malignancies. It is a key component in creating Denintuzumab Mafodotin (SGN-CD19A), an ADC investigated for the treatment of acute lymphoblastic leukemia (ALL).
Key Features:
- Target: Binds specifically to CD19 on B cells.
- Mechanism: Used in ADCs like Denintuzumab Mafodotin to deliver cytotoxic agents to B cells.
- Therapeutic Potential: Explored for treating B-cell malignancies such as ALL.
Applications:
- Cancer Research: Develops ADCs targeting B-cell cancers for targeted treatment.
- Therapeutic Development: Used to synthesize SGN-CD19A for ALL research.
Handling and Storage:
- Storage: Store at -20°C, light-protected.
- Precautions: Use appropriate protective equipment during handling.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
